Dilated Cardiomyopathy (DCM) is a disease of heart muscle that results in a decreased ability of the heart to pump blood. The prognosis for DCM is often poor, with a less than 50% survival rate one year after clinical signs develop, unless a reversible underlying cause is identified. There is no available cure for Dilated Cardiomyopathy, current techniques focus on extending survival time as long as possible. However the focus of this clinical trial is to evaluate a potential curative treatment for cardiomyopathy in the Doberman Pinscher.
Read More
Hemangiosarcoma is the most common splenic cancer diagnosed in dogs. The standard of care treatment is splenectomy (surgery) followed by doxorubicin chemotherapy, but long-term survival remains poor. We are continuously looking for additional well-tolerated treatments that may prolong survival for dogs with this disease.
Read More
Your dog must not be on any supplements such as Yunnan baiyao or I'm Yunity/turkey tail mushroom.
Your dog must not have evidence of metastasis (spread of disease).
Osteosarcoma is a common cancer diagnosed in dogs, particularly in large breed dogs. While several chemotherapy protocols have been shown to provide modest management of the onset of metastasis (spread of cancer), we are continuously looking for additional treatments that may extend survival time. Carboplatin is a widely accepted chemotherapy agent used in treatment of osteosarcoma. The results of this study will allow us to determine if dogs can successfully tolerate carboplatin and a new drug called Laverdia-CA1 (verdinexor) in a combination protocol.
Read More
Patients must have been previously treated at Cornell University Hospital for Animals
Patients must had been diagnosed with osteosarcoma and had limb amputation at Cornell University Hospital for Animals previously.
Patients must not have received chemotherapy treatment previously
Diagnosis of coccidioidomycosis in dogs is challenging due to the fact that the symptoms are not specific for this disease. Coccidioidomycosis can be diagnosed via a biopsy however the most common method is testing for antibodies to the fungus. These tests are often sent to third party labs delaying confirmation of the disease. This study looks to evaluate a potential point of care rapid test which would be able to provide a positive or negative result indicating the presence or absence of antibodies, respectively, within 30-60 minutes. The diagnosis of pulmonary coccidioidomycosis can be difficult because clinical signs overlap with many other respiratory tract disorders and dogs can have positive Valley Fever antibody titers without active clinical infection. Acute phase proteins are useful biomarkers for many other disorders and our hope is to determine whether they can facilitate making a diagnosis of pulmonary coccidioidomycosis in dogs. For additional details or questions please contact Dr. Jaffey ([email protected]).
Read More
Your dog has a a confirmed or suspected novel diagnosis of pulmonary coccidioidomycosis
Your dog has one of the following respiratory signs:
Cough
Exercise intolerance
Wheezing
Dyspnea
Tachypnea
Respiratory distress
Dog must not have received an anti-fungal treatment for more than 7 days before enrollment
Canine chronic bronchitis is an inflammatory disease characterized by a cough for > 2 months without another identifiable cause. Dogs with chronic bronchitis have persistent airway neutrophilic inflammation. The foundation of long-term therapy is corticosteroids. Oral prednisone is commonly used but has a litany of possible adverse effects. Inhaled steroids is an alternative to avoid the adverse effects of prednisone but the only available option is fluticasone. This medication is expensive and has variable efficacy. Inhaled budesonide is a medication used in humans to treat a similar airway disorder and is a fraction of the cost. This study aims to investigate the benefit of inhaled budesonide on respiratory tract symptoms in dogs with chronic bronchitis.
Read More
Dogs with a history of cough exceeding two months may be eligible for the study.
Thoracic radiographs will be used by principal investigator to determine eligibility.
Dogs with alternative caused for chronic cough such as tracheal collapse, heart disease, cancer, Valley Fever, etc are not eligible for this study.
Dogs who have received previously received corticosteroids for treatment of chronic cough are not eligible for this study.
